NEW YORK, Oct. 24 (GenomeWeb News) Monogram Biosciences will use its eTag assays to conduct a cancer biomarker study on Erbitux (cetuximab), Merck KGaA's IgG1 monoclonal antibody, Monogram said today.
Monogram, formerly ViroLogic, will test formalin-fixed, paraffin-embedded tumor samples from patients with colorectal cancer before they are treated with Erbitux, which specifically targets the epidermal growth factor receptor found on many cancer cells. After testing the samples for EGFR-containing receptor dimers, both companies will compare Monogram's predictions of response based with actual clinical outcomes.
Merck KGaA will make payments to Monogram for the project. Other financial details were not disclosed.
Monogram said that it has used its eTag assays to identify activated drug targets or signaling pathways and their correlation with drug activity in nine similar collaborations with pharmaceutical and biotechnology companies.